咨詢熱線
15000266580
15000266580
當(dāng)前位置：首頁 >產(chǎn)品中心>細胞庫>人腫瘤細胞、癌細胞>Panc 04.03細胞， 人胰腺癌細胞
簡要描述：Panc 04.03細胞， 人胰腺癌細胞ATCC 細胞|細胞系|細胞株|腫瘤細胞|細胞；細胞庫管理規(guī)范，提供的細胞株背景清楚，提供參考文獻和*培養(yǎng)條件！
產(chǎn)品型號：廠商性質(zhì)：生產(chǎn)廠家 更新時間：2024-08-29訪 問 量：1682 產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細介紹
Panc 04.03細胞， 人胰腺癌細胞
Panc 04.03 (ATCC® CRL-2555™)
Organism Homo sapiens, human
Tissue pancreas
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease adenocarcinoma
Age 70 years adult
Gender male
Ethnicity White
Storage Conditions liquid nitrogen vapor phase
Derivation Panc 04.03 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.
Clinical Data 70 years
Caucasian
male
Antigen Expression MHC class I +; MHC class II -
RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
Blood type O; Rh+
Oncogene K-ras + RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
Genes Expressed cytokeratins 7 and 18 RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
Tumorigenic Yes
Effects Yes, forms tumors in nude or SCID mice
Comments The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
The cells have a reported plating efficiency of 80%. Ref
Panc 04.03細胞， 人胰腺癌細胞
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
•20 Units/ml human recombinant insulin
•fetal bovine serum to a final concentration of 15%
Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
1.Remove and discard culture medium.
2.Briefly rinse the cell layer with 0.25% (w/v) Trypsin-053mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
3.Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4.Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
5.Add appropriate aliquots of the cell suspension to new culture vessels.
6.Incubate cultures at 37°C.
Subc*tion Ratio: 1:2 to 1:3
Medium Renewal: Add media once per week. Fluid change one to two times per week.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a Manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.
Cryopreservation Complete growth medium supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X.
Culture Conditions Temperature: 37°C
產(chǎn)品咨詢
郵箱：xiangfbio@163.com
地址：上海市虹口區(qū)四平路710號7層
掃一掃 微信咨詢